[1] Kim SB, et, al. 887P Final results and biomarker analysis from a phase I dose-expansion (part II) study of ISU104 (barecetamab; a novel anti-ErbB3) monotherapy or in combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). VOLUME 32, SUPPLEMENT 5, S797, SEPTEMBER 01, 2021.
